Bio Blast Pharma Company Profile (NASDAQ:ORPN)

Analyst Ratings

Consensus Ratings for Bio Blast Pharma (NASDAQ:ORPN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.75 (1,272.83% upside)

Analysts' Ratings History for Bio Blast Pharma (NASDAQ:ORPN)
Show:
DateFirmActionRatingPrice TargetActions
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Roth CapitalReiterated RatingBuy$23.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016HC WainwrightInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/27/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Bio Blast Pharma (NASDAQ:ORPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/19/2016        
5/25/2016Q1($0.29)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.25)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q3($0.29)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/21/2015Q2($0.28)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/19/2015Q115($0.25)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015Q414($0.16)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/21/2014($0.09)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/29/2014Q214($0.09)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio Blast Pharma (NASDAQ:ORPN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.26)($0.30)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio Blast Pharma (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio Blast Pharma (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Bio Blast Pharma (NASDAQ:ORPN)
DateHeadline
07/26/16 08:56 AMTrending Stock Analysis: Bio Blast Pharma Ltd. (NASDAQ:ORPN) - News Oracle
07/25/16 05:51 PMCan Shares Of Bio Blast Pharma Ltd. (NASDAQ:ORPN) Hit $19? - Investor Newswire
07/21/16 06:00 PMChecking in on Stock Volatility for: Bio Blast Pharma Ltd. (NASDAQ:ORPN) - Engelwood Daily
07/21/16 06:00 PMBroker Outlook For Bio Blast Pharma Ltd. (ORPN) - Fiscal Standard
07/19/16 06:36 AMTop Stories: Bio Blast Pharma (NASDAQ:ORPN), Neptune Technologies & Bioressources (NASDAQ:NEPT), Ellington ... - KC Register
07/19/16 06:36 AMNext Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN) - Fiscal Standard
07/19/16 06:36 AMIs $19 Price Target Attainable For Bio Blast Pharma Ltd. (NASDAQ:ORPN)? - Investor Newswire
07/19/16 06:36 AMWere Analysts Bearish Bio Blast Pharma Ltd (NASDAQ:ORPN) This Week? - Press Telegraph
07/16/16 05:12 PMShares Moving Down on the Week: Bio Blast Pharma Ltd. (NASDAQ:ORPN) - Engelwood Daily
07/12/16 05:57 PMStrong Sell Calls For Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 0 - Investor Newswire
07/11/16 05:41 PMBio Blast Pharma Ltd. Stock Momentum Hits Extreme Weakness - CML News
07/11/16 05:41 PMHow Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bullish? - Consumer Eagle
07/05/16 10:10 AMBroker Outlook For The Week Ahead Bio Blast Pharma Ltd. (ORPN) - Fiscal Standard
07/01/16 07:29 AMTesaro (TSRO) in Focus: Stock Adds 8.6% in Session -
06/30/16 05:58 PMBio Blast Pharma Ltd. (ORPN) Updated Price Targets - FTSE News
06/29/16 07:30 AMCalithera Biosciences (CALA) Jumps: Stock Rises 7.6% -
06/27/16 05:39 PMStrong Sell Calls Recommendations For Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 0 - Investor Newswire
06/27/16 09:50 AMAre Analysts Bearish Bio Blast Pharma Ltd (NASDAQ:ORPN) After Last Week? - Engelwood Daily
06/24/16 08:15 AMRetrophin (RTRX) RE-024 Positive in Physician-Initiated Study
06/23/16 07:25 AMArQule (ARQL) Shows Strength: Stock Adds 8% in Session -
06/20/16 05:30 PMStrong Buy Calls Count For Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 2 - Investor Newswire
06/20/16 07:17 AMThis Weeks Broker Views For Bio Blast Pharma Ltd. (ORPN) - Fiscal Standard
06/16/16 09:52 AMBio Blast Pharma Ltd. (ORPN) Current Analyst Ratings - Fiscal Standard
06/16/16 07:31 AMShould You Get Rid of Valeant Pharmaceuticals (VRX) Now? -
06/14/16 05:24 PMResolute Forest Products Inc. (NYSE:RFP) plummeted -6.48%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), Avnet, Inc ... - KC Register
06/13/16 05:15 PMZafgen (ZFGN) Presents Favorable New Data on Beloranib
06/13/16 08:38 AMNew Strong Buy Stocks for June 13th
06/09/16 08:39 AMBioBlast Pharma (ORPN) Plans Trehalose IV Phase 2b in OPMD; Will Evaluate in Other Orphan Diseases - StreetInsider.com
06/09/16 05:02 AM6:02 am Bio Blast Pharma announces plans to initiate a Phase 2b trial with trehalose IV solution in OPMD during the second half of 2016, CFO to leave the co, CEO Colin Foster leaves position but remains on the Board, Executive Chairman Fred -
06/09/16 05:00 AMBioblast Pharma Updates Corporate Plans - [GlobeNewswire] - Trehalose Phase 2 b Trial in Oculopharyngeal Muscular Dystrophy On Track to Commence During the Second Half of 2016. Focus On Trehalose As a Potential Platform. Corporate Restructuring and Management Changes: ...
06/06/16 09:22 AMNokia Corporation (ADR) (NYSE:NOK) increased 0.53%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), IdaCorp, Inc. (NYSE ... - KC Register
06/06/16 09:22 AMMakeMyTrip Limited (NASDAQ:MMYT) decreased -2.35%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), Pacira ... - KC Register
06/02/16 10:18 AM5 Stocks Under $5 With Potential (SIRI,GRPN,KTOS) -
05/31/16 12:17 AMAnalysts Expect Bio Blast Pharma Ltd (NASDAQ:ORPN) to Post ($0.29) EPS - Let Me Know About This - Analysts Expect Bio Blast Pharma Ltd (NASDAQ:ORPN) to Post ($0.29) EPSLet Me Know About ThisBio Blast Pharma logo Shares of Bio Blast Pharma Ltd (NASDAQ:ORPN) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research ...Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsHow Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusFranklin Independentall 5 news articles »
05/30/16 05:46 PMNext Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN) - Share Trading News - Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsBio Blast Pharma Ltd. has a 50 day moving average of 2.16 and a 200 day moving average of 3.11. The stock's market capitalization is 28.18M, it has a 52-week low of 1.65 and a 52-week high of 8.50. The share price of the company (ORPN) was down ...How Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusIs it Time to Cash in Profits on Bio Blast Pharma Ltd. (NASDAQ:ORPN)Franklin Independentall 5 news articles »
05/30/16 05:46 PMNext Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN) - Share Trading News - Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsBio Blast Pharma Ltd. has a 50 day moving average of 2.16 and a 200 day moving average of 3.11. The stock's market capitalization is 28.18M, it has a 52-week low of 1.65 and a 52-week high of 8.50. The share price of the company (ORPN) was down ...How Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusIs it Time to Cash in Profits on Bio Blast Pharma Ltd. (NASDAQ:ORPN)Franklin Independentall 5 news articles »
05/25/16 10:56 AMBio Blast posts 1Q loss -
05/25/16 07:00 AMBioblast Pharma Reports First Quarter 2016 Financial Results - [GlobeNewswire] - NEW HAVEN, Conn., May 25, 2016-- Bioblast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2016.. “During ...
05/25/16 07:00 AMBioblast Pharma Reports First Quarter 2016 Financial Results - [GlobeNewswire] - NEW HAVEN, Conn., May 25, 2016-- Bioblast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2016.. “During ...
04/14/16 03:05 PMBioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting - [GlobeNewswire] - NEW HAVEN, Conn., April 14, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2 ...
04/14/16 03:05 PMBioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting - [GlobeNewswire] - NEW HAVEN, Conn., April 14, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2 ...
03/20/16 09:35 AM4 Key Biopharma Movers of the Past Week -
03/20/16 09:35 AM4 Key Biopharma Movers of the Past Week -
03/17/16 07:15 AMBio Blast Pharma (ORPN) in Focus: Stock Moves Up 54.5% -
03/17/16 07:15 AMBio Blast Pharma (ORPN) in Focus: Stock Moves Up 54.5% -
03/17/16 06:00 AMBioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering - [GlobeNewswire] - NEW HAVEN, Conn., March 17, 2016-- BioBlast Pharma Ltd. announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the ...
03/17/16 06:00 AMBioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering - [GlobeNewswire] - NEW HAVEN, Conn., March 17, 2016-- BioBlast Pharma Ltd. announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the ...
03/16/16 02:18 PMWhy Oracle (ORCL), Celator Pharma (CPXX), Peabody Energy (BTU) and Others Are Trending Today -
03/16/16 02:18 PMWhy Oracle (ORCL), Celator Pharma (CPXX), Peabody Energy (BTU) and Others Are Trending Today -
03/16/16 09:45 AMBio Blast Pharma Explodes on Positive Results -

Social

About Bio Blast Pharma

Bio Blast Pharma logoBio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company is advancing its Cabaletta platform product candidates through clinical development and advancing its other product candidates, BB-FA, BB-OTC, and BBrm1, as well as its other early stage research projects, through preclinical development. The Company's three principal product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform. The Company is developing Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD); spinocerebellar ataxia type 3 (SCA3), and Spinobulbar Muscular Atrophy (SBMA). It is conducting preclinical studies of BBrm1 for the treatment of Spinal Muscular Atrophy (SMA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORPN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.74
  • 50 Day Moving Average: $1.72
  • 200 Day Moving Average: $2.35
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $24.74M
  • Beta: -0.05
  • Current Year EPS Consensus Estimate: $-1.20 EPS
  • Next Year EPS Consensus Estimate: $-0.98 EPS
Additional Links:
Bio Blast Pharma (NASDAQ:ORPN) Chart for Thursday, July, 28, 2016